Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Articles
BioCentury
|
Oct 21, 2002
Clinical News
Coenzyme Q10: Phase II
...from placebo. The study was funded by the National Institute of Neurological Disorders and Stroke.
Vitaline Corp.
...
Read More
BioCentury
|
Aug 20, 2001
Clinical News
Coenzyme Q10: Phase III
...a trend toward improving the degree of chorea. Remacemide is an NMDA glutamate receptor blocker.
Vitaline Corp.
...
Read More
Items per page:
10
1 - 2 of 2
BioCentury
|
Oct 21, 2002
Clinical News
Coenzyme Q10: Phase II
...from placebo. The study was funded by the National Institute of Neurological Disorders and Stroke.
Vitaline Corp.
...
Read More
BioCentury
|
Aug 20, 2001
Clinical News
Coenzyme Q10: Phase III
...a trend toward improving the degree of chorea. Remacemide is an NMDA glutamate receptor blocker.
Vitaline Corp.
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page